Neumora Therapeutics (NMRA) Assets Average (2023 - 2026)

Neumora Therapeutics' Assets Average history runs 4 years deep, the most recent figure standing at $172.5 million for Q1 2026.

• On a quarterly basis, Assets Average fell 39.88% year-over-year to $172.5 million in Q1 2026; TTM through Mar 2026 was $172.5 million, a 39.88% decrease from a year earlier, with the FY2025 full-year figure at $254.0 million, down 37.53% from the prior year.
• Assets Average eased to $172.5 million in Q1 2026 per NMRA's latest filing, from $184.4 million in the prior quarter.
• Across five years, Assets Average topped out at $520.5 million in Q4 2023 and bottomed at $172.5 million in Q1 2026.
• The 4-year median for Assets Average is $310.8 million (2024), against an average of $321.9 million.
• Across the five-year window, Assets Average tumbled 35.68% in 2024 and tumbled 46.94% in 2025, its largest moves.
• Year by year, Assets Average stood at $520.5 million in 2023, then tumbled by 35.68% to $334.8 million in 2024, then tumbled by 44.9% to $184.4 million in 2025, then slipped by 6.49% to $172.5 million in 2026.
• Per Business Quant, the three latest NMRA Assets Average figures stand at $172.5 million (Q1 2026), $184.4 million (Q4 2025), and $200.8 million (Q3 2025).